- Home
- OCEA vs FBGL Comparison
OCEA vs FBGL Comparison
Compare OCEA & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEA
- FBGL
- Stock Information
- Founded
- OCEA 2019
- FBGL 1996
- Country
- OCEA United States
- FBGL Singapore
- Employees
- OCEA N/A
- FBGL N/A
- Industry
- OCEA Biotechnology: Pharmaceutical Preparations
- FBGL Miscellaneous manufacturing industries
- Sector
- OCEA Health Care
- FBGL Consumer Discretionary
- Exchange
- OCEA Nasdaq
- FBGL Nasdaq
- Market Cap
- OCEA 20.5M
- FBGL 23.6M
- IPO Year
- OCEA N/A
- FBGL 2025
- Fundamental
- Price
- OCEA $0.13
- FBGL $1.02
- Analyst Decision
- OCEA
- FBGL
- Analyst Count
- OCEA 0
- FBGL 0
- Target Price
- OCEA N/A
- FBGL N/A
- AVG Volume (30 Days)
- OCEA 88.9M
- FBGL 1.9M
- Earning Date
- OCEA 01-13-2025
- FBGL 01-01-0001
- Dividend Yield
- OCEA N/A
- FBGL N/A
- EPS Growth
- OCEA N/A
- FBGL N/A
- EPS
- OCEA N/A
- FBGL 0.04
- Revenue
- OCEA N/A
- FBGL $15,607,369.00
- Revenue This Year
- OCEA N/A
- FBGL N/A
- Revenue Next Year
- OCEA N/A
- FBGL N/A
- P/E Ratio
- OCEA N/A
- FBGL $27.55
- Revenue Growth
- OCEA N/A
- FBGL 25.78
- 52 Week Low
- OCEA $0.11
- FBGL $0.87
- 52 Week High
- OCEA $7.79
- FBGL $5.45
- Technical
- Relative Strength Index (RSI)
- OCEA 28.02
- FBGL N/A
- Support Level
- OCEA $0.12
- FBGL N/A
- Resistance Level
- OCEA $0.16
- FBGL N/A
- Average True Range (ATR)
- OCEA 0.04
- FBGL 0.00
- MACD
- OCEA 0.01
- FBGL 0.00
- Stochastic Oscillator
- OCEA 8.66
- FBGL 0.00
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.